SCHEMBL20601375

SCHEMBL20601375

Cc1ccc(C(=O)NC(CC2CCN(C(=O)OC(C)(C)C)CC2)c2ccccc2)cn1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.52
PKM P14618 1/20 0.52
YAP1 P46937 3/20 0.45
KMT2A Q03164 2/20 0.45
MAPK1 P28482 2/20 0.44
USP30 Q70CQ3 1/20 0.44
GPR119 Q8TDV5 4/20 0.44
STS P08842 1/20 0.43
LIMK2 P53671 1/20 0.42
MEN1 O00255 1/20 0.42
POLB P06746 1/20 0.42
MAPT P10636 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
GPR55 Q9Y2T6 1/20 0.42
HPGDS O60760 1/20 0.41
ITGB3 P05106 1/20 0.41
ITGA2B P08514 1/20 0.41
LMNA P02545 1/20 0.41
THRB P10828 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20601240 0.90 KDM4E (0.50) KDM4EPKMYAP1KMT2AMAPK1
SCHEMBL23088074 0.90 KDM4E (0.50) KDM4EPKMYAP1KMT2AMAPK1
SCHEMBL20601276 0.88 KDM4E (0.55) KDM4EPKMYAP1GPR119
SCHEMBL20618562 0.88 GPR119 (0.51) KDM4EPKMYAP1KMT2AMAPK1
SCHEMBL20601482 0.88 KDM4E (0.59) KDM4EPKMYAP1KMT2AGPR119
SCHEMBL20601233 0.88 KDM4E (0.66) KDM4EPKMYAP1KMT2AMAPK1
SCHEMBL20601549 0.86 KDM4E (0.59) KDM4EPKMYAP1KMT2AMAPK1
SCHEMBL20601318 0.85 KDM4E (0.58) KDM4EPKMYAP1KMT2ASTS
SCHEMBL20601477 0.85 KDM4E (0.58) KDM4EPKMYAP1KMT2AMAPK1
SCHEMBL20618718 0.85 KDM4E (0.58) KDM4EPKMYAP1KMT2AMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210078988-A1 MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2021-03-18 US disclosed
US-20210078988-A1 MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2021-03-18 US disclosed
EP-3645519-A1 MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE GlaxoSmithKline Intellectual Property Development Limited (GB) 2020-05-06 EP disclosed
CN-110770222-A Modulators of indoleamine2, 3-dioxygenase 葛兰素史克知识产权开发有限公司 2020-02-07 CN disclosed
WO-2019003142-A1 MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2019-01-03 WO disclosed
WO-2019003142-A1 MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2019-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210078988-A1 MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE IDO1, IDO2, TPH1 KDM4E 657/4885PKM 892/4885YAP1 2221/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.